
Opinion|Videos|April 28, 2025
Practical Considerations for Managing Atopic Dermatitis With Biologics
Panelists discuss how biologic therapy management requires strategic monitoring with initial assessment at 4 to 12 weeks, defining nonresponse at 12 to 16 weeks, addressing adherence before considering alternatives such as switching biologics with different mechanisms or transitioning to JAK inhibitors based on comorbidities, coverage, administration preferences, and safety considerations—emphasizing that the expanding therapeutic landscape enables personalized approaches that have transformed expectations for moderate to severe atopic dermatitis.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- When you start a patient on a biologic, how often are you monitoring the patient’s treatment regimen for effectiveness?
- When do you consider a patient a nonresponder to their current treatment?
- If a patient is not responding to their current biologic or discontinues it for any reason, what would be your next approach to treatment?
- Do you have any practice pearls for adherence for potential nonresponders?
- What impact would switching to another systemic therapy with a different mechanism of action have on the patient?
- How would you decide whether to switch to another biologic or switch to an oral JAK inhibitor?
- What closing thoughts do you have on the use of biologics in moderate to severe atopic dermatitis?
Advertisement
Related to this article

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
Ruvonoflast Reduces hsCRP, Inflammation, CVD Risk With Downstream Effects
3
Lessons From ZEUS on Targeting Inflammation, With Peter Libby, MD
4
Monthly PVX108 Raises Peanut Tolerance in Children, With Brian Vickery, MD
5

